电邮这篇文章 Left ventricle myocardial hypertrophy in women with arterial hypertension: justification of medical tactics
- 作者: Kislyak O.1, Starodubova A.1
-
隶属关系:
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- 期: 卷 6, 编号 2 (2015)
- 页面: 64-68
- 栏目: Articles
- URL: https://journals.rcsi.science/2221-7185/article/view/45169
- DOI: https://doi.org/10.26442/CS45169
- ID: 45169
如何引用文章
全文:
详细
Arterial hypertension (AH) is the most common cardiovascular disease risk factor. After the menopause the prevalence of AH in women greatly exceeds than in men. Hemodynamic characteristics in case of AH in postmenopausal women determine the higher risk and the speed of left ventricle myocardial hypertrophy (LMVH), diastolic and systolic dysfunction development. There 80 women aged 44-62 years (mean age of 53.2±4.1 years) in the early postmenopausal period were enrolled in the study and we found that the main influence on LV mass index and LMVH in addition to AH and the level of systolic blood pressure play the body mass index, the level of diastolic blood pressure and the indicators characterizing the distribution of adipose tissue, presence of abdominal obesity. Guidelines for the treatment of AH in men and women have no fundamental differences. However, taking into account the high prevalence of obesity, isolated systolic hypertension and LMVH in women with AH in postmenopausal period, the drugs of choice become angiotensin receptor blocker (ARBs) and the combinations of antihypertensive drugs on the basis of the ARBs, all these data for the first time ever were shown in the study LIFE concerning the application of losartan in the treatment.
作者简介
O. Kislyak
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. каф. факультетской терапии Московского факультета ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
A. Starodubova
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: antoninastarodubova@yandex.ru
канд. мед. наук, ассистент каф. госпитальной терапии №2 лечебного фа- культета ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
参考
- Vasan S.R, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle - aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003-10.
- Фролова О.Г. Репродуктивное здоровье женщины. Качество жизни. Медицина. 2004; 9: 9-12.
- Lloyd-Jones D.M, Larson M.G, Leip E.P et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-72.
- Подзолков В.И., Можарова Л.Г., Холицкая Ю.В. Кардиологические аспекты менопаузы. Сердце. 2003; 2: 300-3.
- Kannel W.B, Cobb J. Left ventricular hypertrophy and mortality: results from the Framingham Study. Cardiology 1992; 81: 291-8.
- Ganau A, Devereux R.B, Pickering T.G. Relation of left ventricular homodynamic load and contactile performance to left ventricular mass in hypertension. Circulation 1990; 81: 25-36.
- Morricone L, Malavazos F.E, Coman C et al. Echocardioraphic abnormalities in Normotensive Obese Patients: Relationship with visceral fat. Obes Res 2002; 10: 489-98.
- Mac Mahon S.W, Wilcken D.L, Mac Douck G.Y. The effect of weight reduction on left ventricular mass. NEJM 1986; 314: 334-9.
- Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Сист. гипертензии. 2010; 3: 5-26.
- Чукаева И.И., Клепикова М.В., Орлова Н.В. и др. Выраженность маркеров воспаления у женщин с артериальной гипертензией и ожирением на фоне нарушений липидного обмена. Сист. гипертензии. 2011; 1: 48-53.
- Staessen J.A, Bieniazewsk L, Brosens I et al. The epidemiology of Hypertension and its association with cardiovascular disease. in Messrli F. (ed.). Hypertension and other cardiovascular risk factors after the menopause. New York, Marsel Dekker Inc. 1995; p. 43-78.
- Bella J.N, Devereux R.B, Roman M.J et al. Relations of left ventricular mass to fat free and adipose body mass: The strong Heart Study. Circulation 1998; 98: 2538-44.
- Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы. Сист. гипертензии. 2010; 4: 5-9.
- Klingbeil A.U, Schneider M, Martus P et al. A meta - analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6.
- Karnik S.S, Unal H. Angiotensin II Receptor - induced cardiac remodeling in mice without Angiotensin II. Hypertension 2012; 59: 542-5.
- Gudmundsdottir H, Hoieggen A, Stenehjem A et al. Hypertension in women: latest findings and clinical implications. Ther Adv Chronic Dis 2012; 3: 137-44.
- Os I, Franco V, Kjeldsen S.E et al. Effects of Losartan in women with hypertension and left ventricular hypertrophy. Results from the Losartan intervention for endpoint reduction of hypertension study. Hypertension 2008; 51: 1103-8.
- Agabiti-Roseli E, Salvetti M. Gender differences in the regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy. Hypertension 2008; 52: 59-60.
- Чихладзе Н.М., Сахнова Т.А., Блинова Е.В. и др. Эффективность лозартана у больных артериальной гипертонией с гипертрофией миокарда левого желудочка. Сист. гипертензии. 2011; 4: 26-32.
